ABSTRACT
A novel route for the valorization of waste into valuable products was developed. Surgical masks commonly used for COVID 19 protection by stopping aerosol and droplets have been widely used, and their disposal is critical and often not properly pursued. This work intended to transform surgical masks into platinum group metal-free electrocatalysts for oxygen reduction reaction (ORR) and hydrogen evolution reaction (HER) as well as into crude oil. Surgical masks were subjected to controlled-temperature and -atmosphere pyrolysis, and the produced char was then converted into electrocatalysts by functionalizing it with metal phthalocyanine of interest. The electrocatalytic performance characterization towards ORR and HER was carried out highlighting promising activity. At different temperatures, condensable oil fractions were acquired and thoroughly analyzed. Transformation of waste surgical masks into electrocatalysts and crude oil can open new routes for the conversion of waste into valuable products within the core of the circular economy.
Subject(s)
COVID-19 , Petroleum , Humans , Masks , Pyrolysis , SARS-CoV-2ABSTRACT
In a system already preconditioned by previous damage, as results of the cytokine release syndrome complicating the COVID-19 disease, a small trigger may be sufficient to develop a SIADH complicating a GBS, even without a poor outcome.
ABSTRACT
We report a case of Guillain-Barré syndrome (GBS) following the first dose of Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. As the COVID-19 vaccination campaign progresses worldwide, GBSs vaccine-related have been increasingly reported. After reviewing the available literature, considering the annual incidence of GBS, in this historical moment, the public health systems cannot afford an unjustified distrust in vaccines, caused by misinterpretation of epidemiological data. Nonetheless, it is important for clinicians to promptly recognize neurological complications potentially associated with COVID-19 vaccinations and report them to pharmacovigilance agencies.